羟氯喹治疗COVID-19肺炎的疗效和安全性:数据的不确定性和不断变化的治疗方案

Tarig Fadelelmoula
{"title":"羟氯喹治疗COVID-19肺炎的疗效和安全性:数据的不确定性和不断变化的治疗方案","authors":"Tarig Fadelelmoula","doi":"10.15406/jlprr.2020.07.00228","DOIUrl":null,"url":null,"abstract":"The new coronavirus disease which emerged in Wuhan late in 2019 is caused by SARS CoV2, it was named COVID-19 and declared a pandemic by the world health organization (WHO). Human coronavirus normally causes mild disease. The new COVID-19 emerged from bats to human and it’s associated with highly infectious disease. The disease clinical features range from an asymptomatic state to mild fever, cough, severe respiratory disease, and multiple organ failures. The disease is confirmed by detecting the virus genome using polymerase chain reaction and antibody detection is used for screening. Radiologic imaging is nonspecific but can help in staging lung involvement. Treatment of patients with COVID-19 is generally supportive, however oxygen and ventilatory support might be needed in some of the cases. Dexamethasone proved to decrease mortality in critically ill patients, but up to date no specific treatment or vaccine is available and many drugs are under clinical trials including ritonavir and remdesivir. Hydroxychloroquine (HCQ) which is an old antimalarial drug, has given hope, but now it’s a victim for information uncertainty and contravention of clinical reports. The objective of this article is to review the current reports on hydroxychloroquine efficacy and safety in the treatment of COVID 19 patients.","PeriodicalId":91750,"journal":{"name":"Journal of lung, pulmonary & respiratory research","volume":"46 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-09-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Efficacy and safety of Hydroxychloroquine in treating COVID-19 pneumonia: uncertainty of data and changing treatment protocols\",\"authors\":\"Tarig Fadelelmoula\",\"doi\":\"10.15406/jlprr.2020.07.00228\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The new coronavirus disease which emerged in Wuhan late in 2019 is caused by SARS CoV2, it was named COVID-19 and declared a pandemic by the world health organization (WHO). Human coronavirus normally causes mild disease. The new COVID-19 emerged from bats to human and it’s associated with highly infectious disease. The disease clinical features range from an asymptomatic state to mild fever, cough, severe respiratory disease, and multiple organ failures. The disease is confirmed by detecting the virus genome using polymerase chain reaction and antibody detection is used for screening. Radiologic imaging is nonspecific but can help in staging lung involvement. Treatment of patients with COVID-19 is generally supportive, however oxygen and ventilatory support might be needed in some of the cases. Dexamethasone proved to decrease mortality in critically ill patients, but up to date no specific treatment or vaccine is available and many drugs are under clinical trials including ritonavir and remdesivir. Hydroxychloroquine (HCQ) which is an old antimalarial drug, has given hope, but now it’s a victim for information uncertainty and contravention of clinical reports. The objective of this article is to review the current reports on hydroxychloroquine efficacy and safety in the treatment of COVID 19 patients.\",\"PeriodicalId\":91750,\"journal\":{\"name\":\"Journal of lung, pulmonary & respiratory research\",\"volume\":\"46 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-09-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of lung, pulmonary & respiratory research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15406/jlprr.2020.07.00228\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of lung, pulmonary & respiratory research","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15406/jlprr.2020.07.00228","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

摘要

2019年底在武汉出现的新型冠状病毒病是由SARS CoV2引起的,被世界卫生组织(WHO)命名为COVID-19,并宣布为大流行。人类冠状病毒通常引起轻微的疾病。新型COVID-19是从蝙蝠传染给人类的,它与高度传染性疾病有关。该病的临床特征从无症状状态到轻度发烧、咳嗽、严重呼吸系统疾病和多器官衰竭。采用聚合酶链反应检测病毒基因组,并采用抗体检测进行筛选,从而确诊该病。放射学成像是非特异性的,但可以帮助分期肺部受累。COVID-19患者的治疗通常是支持性的,但在某些病例中可能需要氧气和呼吸支持。地塞米松被证明可以降低危重病人的死亡率,但迄今为止还没有专门的治疗方法或疫苗,包括利托那韦和瑞德西韦在内的许多药物正在进行临床试验。羟氯喹(HCQ)是一种古老的抗疟药,它给人们带来了希望,但现在却成为信息不确定和临床报告不符的受害者。本文的目的是综述羟氯喹治疗COVID - 19患者的有效性和安全性的最新报道。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Efficacy and safety of Hydroxychloroquine in treating COVID-19 pneumonia: uncertainty of data and changing treatment protocols
The new coronavirus disease which emerged in Wuhan late in 2019 is caused by SARS CoV2, it was named COVID-19 and declared a pandemic by the world health organization (WHO). Human coronavirus normally causes mild disease. The new COVID-19 emerged from bats to human and it’s associated with highly infectious disease. The disease clinical features range from an asymptomatic state to mild fever, cough, severe respiratory disease, and multiple organ failures. The disease is confirmed by detecting the virus genome using polymerase chain reaction and antibody detection is used for screening. Radiologic imaging is nonspecific but can help in staging lung involvement. Treatment of patients with COVID-19 is generally supportive, however oxygen and ventilatory support might be needed in some of the cases. Dexamethasone proved to decrease mortality in critically ill patients, but up to date no specific treatment or vaccine is available and many drugs are under clinical trials including ritonavir and remdesivir. Hydroxychloroquine (HCQ) which is an old antimalarial drug, has given hope, but now it’s a victim for information uncertainty and contravention of clinical reports. The objective of this article is to review the current reports on hydroxychloroquine efficacy and safety in the treatment of COVID 19 patients.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
A Case of hydropneumothorax Medication resistant tuberculosis: multi drugresistant and extensively drug resistant First aid for acute lung inflammation Continuation of therapeutic anticoagulation before and during hospitalization is associated with reduced mortality in COVID-19 ICU patients Subtyping meconium protease activities which degrade lung protective angiotensin converting enzyme-2 in human lung cells
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1